Literature DB >> 8025225

Neurologic sequelae after treatment of severe hyponatremia: a multicenter perspective.

R H Sterns1, J D Cappuccio, S M Silver, E P Cohen.   

Abstract

Severe, symptomatic hyponatremia is often treated urgently to increase the serum sodium to 120 to 130 mmol/L. Recently, this approach has been challenged by evidence linking "rapid correction" (> 12 mmol/L per day) to demyelinating brain lesions. However, the relative risks of persistent, severe hyponatremia and iatrogenic injury have not been well quantified. Data were sought on patients with serum sodium levels < or = 105 mmol/L from the membership of the American Society of Nephrology. Respondents were given a report form asking specific questions regarding the cause of hyponatremia, presenting symptoms, rate of correction, and neurologic sequelae. Data on 56 patients were analyzed. Fourteen developed posttherapeutic complications (10 permanent, 4 transient) after correction to a serum sodium > 120 mmol/L. Eleven of these 14 patients (including 3 with documented central pontine myelinolysis) had a biphasic course in which neurologic findings initially improved and then worsened on the second to sixth day. Posttherapeutic complications were not explained by age, sex, alcoholism, presenting symptoms, or hypoxic episodes. Increased chronicity of hyponatremia and a high rate of correction in the first 48 h of treatment were significantly associated with complications. No neurologic complications were observed among patients corrected by < 12 mmol/L per 24 h or by < 18 mmol/L per 48 h or in whom the average rate of correction to a serum sodium of 120 mmol/L was < or = 0.55 mmol/L per hour. It was concluded that patients with severe chronic hyponatremia are most likely to avoid neurologic complications when their electrolyte disturbance is corrected slowly.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8025225     DOI: 10.1681/ASN.V481522

Source DB:  PubMed          Journal:  J Am Soc Nephrol        ISSN: 1046-6673            Impact factor:   10.121


  94 in total

Review 1.  Hyponatremia.

Authors:  Jameela Al-Salman; David Kemp; Daniel Randall
Journal:  West J Med       Date:  2002-05

2.  [Hyponatremia: differential diagnosis and therapy].

Authors:  C S Haas
Journal:  Internist (Berl)       Date:  2014-12       Impact factor: 0.743

3.  Hyperkalemia: a threat to RAAS inhibition?

Authors:  Robert W Schrier
Journal:  Nat Rev Nephrol       Date:  2010-05       Impact factor: 28.314

4.  Minocycline prevents osmotic demyelination syndrome by inhibiting the activation of microglia.

Authors:  Haruyuki Suzuki; Yoshihisa Sugimura; Shintaro Iwama; Hiromi Suzuki; Ozaki Nobuaki; Hiroshi Nagasaki; Hiroshi Arima; Makoto Sawada; Yutaka Oiso
Journal:  J Am Soc Nephrol       Date:  2010-10-28       Impact factor: 10.121

Review 5.  Hyponatraemia in clinical practice.

Authors:  M Biswas; J S Davies
Journal:  Postgrad Med J       Date:  2007-06       Impact factor: 2.401

6.  [Hyponatremia].

Authors:  Alexandra Scholze; Martin Tepel
Journal:  Med Klin (Munich)       Date:  2009-02-15

Review 7.  "Dazed and diffused": making sense of diffusion abnormalities in neurologic pathologies.

Authors:  K M O'Connor; G Barest; T Moritani; O Sakai; A Mian
Journal:  Br J Radiol       Date:  2013-10-28       Impact factor: 3.039

8.  Astrocytes are an early target in osmotic demyelination syndrome.

Authors:  Fabrice Gankam Kengne; Charles Nicaise; Alain Soupart; Alain Boom; Johan Schiettecatte; Roland Pochet; Jean Pierre Brion; Guy Decaux
Journal:  J Am Soc Nephrol       Date:  2011-09-01       Impact factor: 10.121

9.  Osmotic Demyelination Syndrome Associated with Hypernatremia Caused by Lactulose Enema in a Patient with Chronic Alcoholism.

Authors:  Jeong Ho Lee; Chang Seong Kim; Eun Hui Bae; Soo Wan Kim; Seong Kwon Ma
Journal:  Electrolyte Blood Press       Date:  2021-06-30

Review 10.  Management of acute kidney injury in children: a guide for pediatricians.

Authors:  Sharon P Andreoli
Journal:  Paediatr Drugs       Date:  2008       Impact factor: 3.022

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.